-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mogamulizumab in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mogamulizumab in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mogamulizumab in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mogamulizumab in Oral Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mogamulizumab in Oral Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mogamulizumab in Oral Cancer Drug Details: Mogamulizumab (Poteligeo) is a glyco-engineered...
-
Thematic Analysis
Consumer Goods M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Consumer Goods Sector
-
Sector Analysis
EMEA Automotive Sport Sponsorship Landscape – Biggest Deals, Trends and Case Studies
EMEA Automotive Sport Sponsorship Landscape Report Overview The annual value of signed automotive deals in the EMEA automotive sports sponsorship market was $227.11 million in 2023. Most of the recent active sponsorship income comes from deals agreed in 2023, which include Volkswagen’s renewal agreement with the German soccer club VfL Wolfsburg, the most lucrative annual deal that commenced in 2023. Annual Value of Automotive Deals Signed ($ Million) Buy the Full Report for more insights into the EMEA Automotive Sport...
-
Analyst Opinions
Dairy and Dairy Alternative Demand Spaces – Top Trends and Industry Insights
Reasons to buy the ‘Dairy and Dairy Alternative Demand Spaces’ report: Understand consumer attitudes and behaviors based on the "five Ws": the who, what, when, where, and whys. Explore and identify how to leverage the top trends in dairy and alternatives in 2024. Gain insight into how competitors and the innovation landscape are responding to this trend. Access valuable strategic take-outs to help direct future decision-making and inform new product and service development. How is our ‘Dairy and Dairy Alternative...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tivozanib in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib in Diabetic Macular Edema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tivozanib in Diabetic Macular Edema Drug Details: Tivozanib is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tivozanib in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tivozanib in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tivozanib in Wet (Neovascular / Exudative) Macular...
-
Product Insights
Cutaneous T-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Cutaneous T-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Cutaneous T-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cutaneous T-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Malignant Pleural Mesothelioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Pleural Mesothelioma - Drugs In Development, 2023’, provides an overview of the Malignant Pleural Mesothelioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Anaplastic Large Cell Lymphoma (ALCL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Anaplastic Large Cell Lymphoma (ALCL) - Drugs In Development, 2023’, provides an overview of the Anaplastic Large Cell Lymphoma (ALCL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...